

**Supplementary Table 1 Timeline of historical and current information**

<b>Time point</b>	<b>Event</b>	<b>Intervention</b>	<b>Outcome</b>
May 2022	Patient visited our clinic because of abnormal vaginal bleeding and an abdominal mass	None	
Jun 2022	Transvaginal us scan showed a 13 cm × 8 cm × 12 cm solid mass posterior to the uterus. Serum beta-hCG was 214405.5 mIU/mL	Optimal debulking was achieved with no macroscopic residual tumor (R0) was performed	Rapid postoperative recovery
Jul 2022	Postoperatively, the serum beta-hCG decreased to 796.7 mIU/ml. Immunohistochemical confirmed the diagnosis of primary pure non-gestational ovarian choriocarcinoma	The adjuvant chemotherapy of BEP protocol was administrated	No adverse reaction
Sep 2022	The serum beta-hCG decreased to normal Level	Two cycles of adjuvant chemotherapy had been performed	No adverse reaction
Dec 2022		Four cycles of adjuvant chemotherapy had been performed	No sign of recurrence and metastasis

beta-hCG: Beta-human chorionic gonadotropin; BEP: Bleomycin, etoposide, and cisplatin.